| First Author | Liu Y | Year | 2020 |
| Journal | Neurosci Lett | Volume | 728 |
| Pages | 134938 | PubMed ID | 32278026 |
| Mgi Jnum | J:289541 | Mgi Id | MGI:6432725 |
| Doi | 10.1016/j.neulet.2020.134938 | Citation | Liu Y, et al. (2020) Multi-target PET evaluation in APP/PS1/tau mouse model of Alzheimer's disease. Neurosci Lett 728:134938 |
| abstractText | Positron emission tomography (PET) has great benefits for developing therapeutics and quantifying pathological markers in neuropsychiatric disorders. This study aimed to firstly demonstrate the feasibility of PET imaging for glucagon-like peptide-1 receptor (GLP-1R) in Alzheimer's disease (AD) and evaluate the GLP-1R expression. Besides, microglial activation, dopamine D2 receptor (D2R) expression, and glucose metabolism in the brain of APP/PS1/tau transgenic model of AD (3xTg-AD) were also investigated by PET. [(18)F]FBEM-Cys(39)-exendin-4, [(18)F]DPA-714, [(18)F]fallypride, and [(18)F]FDG were prepared and PET imaging acquisitions for 3xTg-AD mice and wild-type (WT) mice were performed at 15, 30, and 60 min post-injection. Fifteen regions of interest (ROIs) were selected and %ID/g was calculated. The results showed that the uptake of [(18)F]FBEM-Cys(39)-exendin-4 in 10 ROIs of 3xTg-AD mice at 60 min post-injection was significantly lower than that of WT mice (p < 0.05). Besides, 3xTg-AD mice showed significantly higher [(18)F]DPA-714 uptake in 7 ROIs and lower [(18)F]fallypride uptake in 4 ROIs compared to WT mice. [(18)F]FDG PET showed no significant differences in any ROIs between the two groups. A positive correlation between the uptake of [(18)F]fallypride and [(18)F]FBEM-Cys(39)-exendin-4 could be found in the whole brain. In summary, these results validated the feasibility of GLP-1R PET in AD and demonstrated the reduced GLP-1R and D2R expression as well as increased microglial activation caused by AD. |
